GSTM1、P1基因多态对接受铂类药物辅助化疗的胃癌患者预后的影响  

Prognostic Impact of GSTM1 and GSTP1 Polymorphism on Gastric Cancer Patients Treated with Platinum-based Adjuvant Chemotherapy

作　　者：黄朝晖[1] 华东[1] 李莉华[1] 茆勇[1] 吴小红[1] 

机构地区：[1]苏州大学附属第四医院肿瘤研究所,江苏无锡214062

出　　处：《肿瘤防治研究》2008年第6期411-413,421,共4页Cancer Research on Prevention and Treatment

基　　金：无锡市科技局社会发展计划资助项目(CLZ00612)

摘　　要：目的探讨GSTM1、GSTP1基因多态与胃癌对铂类药物辅助化疗预后的关系。方法确诊的胃癌患者84例,采用铂类药物为主的方案进行辅助化疗;采用聚合酶链反应-连接酶检测反应检测GSTM1和GSTP1 Ile105Val基因多态。结果84例胃癌患者中,43例(51.2%)携带GSTM1缺失基因型;GSTP1 Ile/Ile、Ile/Val和Val/Val分别占61.9%、28.6%和9.7%。携带GSTP1 Ile/Val和Val/Val基因型的胃癌患者无复发生存率和总生存率均显著高于携带Ile/Ile基因型患者(P<0.05)。多因素分析结果显示,GSTP1多态是影响患者复发的独立危险因素(P<0.05)。结论GSTP1 Ile105Val基因多态与接受铂类药物辅助化疗的胃癌患者的预后有关。Objective To investigate the association of GSTM1 and GSTP1 polyrnorphisms with the clinical outcome of gastric cancer patients treated with platinum-based adjuvant chemotherapy. Methods A total of 84 patients with gastric cancer were recruited. All patients received platinum-based adjuvant chemotherapy. PCR-LDR （ligation detection reaction） method was used to detect genotypes of GSTM1- null and GSTP1 Ile105Val. Results Of the 84 patients, the prevalence of the GSTMI-null genotype was 51.2% and the frequencies of GSTP1 Ile/Ile, Ile/Val and Val/Val genotype were 61.9%, 28. 6% and 9. 7%, respectively. The reeurrence-free survival rate and overall survival rate in patients with GSTP1 Ile/Val and Val/Val genotype were significantly higher than those in patients with lie/lie genotype （P〈0. 05）. Multivariable analysis showed that GSTP1 Ile/Ile genotype was associated with shorter recurrence-free survival （P〈0. 05）. Conclusion Polymorphism of GSTP1 Ile105Val may be a potential prognostic factor in gastric cancer patients treated with platinum-based adjuvant chemotherapy.

关 键 词：胃癌 化学治疗 多态性 谷胱甘肽S转移酶 

分 类 号：R735.2[医药卫生—肿瘤]